# Recombinant Human IDO1/IDO Protein (His Tag)

Catalog Number: PKSH032584



Note: Centrifuge before opening to ensure complete recovery of vial contents.

		crip				
	00	CI	РΤ	n	tπ	Λn
JU.	$\mathbf{c}$	v.		w	ш	UП

 Species
 Human

 Mol\_Mass
 46.8 kDa

 Accession
 P14902

**Bio-activity** Measured by its ability to oxidize L-tryptophan to N-formyl-kynurenine. The specific

activity is 5166. 667 pmol/min/µg pmol/min/µg.

# **Properties**

**Purity** > 95 % as determined by reducing SDS-PAGE.

**Endotoxin** < 1.0 EU per  $\mu$ g of the protein as determined by the LAL method.

Storage Storage Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles.

**Shipping** This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel


packs. Upon receipt, store it immediately at < - 20°C.

Formulation Supplied as a 0.2 μm filtered solution of 20mM Sodium Acetate, 150mM NaCl, 20%

Glycerol, pH 4.5.

**Reconstitution** Not Applicable

### Data



> 95 % as determined by reducing SDS-PAGE.

# **Background**

Indoleamine 2,3-dioxygenase (IDO) is a heme enzyme that initiates the oxidative degradation of the least abundant, essential amino acid, l-tryptophan, along the kynurenine pathway. This protein is normally expressed in the dendritic cells, macrophages, microglia, eosinophils, fibroblasts, endothelial cells, and most tumor cells. IDO activity is associated with immunosuppression and immune attenuation. Several studies showed that IDO can contribute to immune escape when expressed directly in tumor cells or when expressed in immunosuppressive antigen presenting cells such as tolerogenic dendritic cells or tumor associated macrophages. IDO also is a promising therapeutic target for the treatment of cancer, chronic viral infections, and other diseases characterized by pathological immune suppression.

# For Research Use Only